Nu Skin Enterprises (NYSE:NUS) issued an update on its fourth quarter earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of $1.04-1.11 for the period, compared to the Thomson Reuters consensus estimate of $1.13. The company issued revenue guidance of $665-685 million, compared to the consensus revenue estimate of $665.95 million.

Shares of NYSE:NUS traded down $8.77 during midday trading on Thursday, reaching $64.05. 23,561 shares of the company were exchanged, compared to its average volume of 409,570. Nu Skin Enterprises has a fifty-two week low of $60.15 and a fifty-two week high of $88.68. The company has a quick ratio of 1.19, a current ratio of 1.82 and a debt-to-equity ratio of 0.46. The firm has a market cap of $4.04 billion, a price-to-earnings ratio of 19.87, a PEG ratio of 1.78 and a beta of 1.04.

Nu Skin Enterprises (NYSE:NUS) last issued its quarterly earnings data on Wednesday, November 7th. The company reported $0.94 EPS for the quarter, missing analysts’ consensus estimates of $0.96 by ($0.02). Nu Skin Enterprises had a return on equity of 25.67% and a net margin of 5.74%. The company had revenue of $675.31 million for the quarter, compared to analyst estimates of $664.99 million. During the same quarter in the previous year, the business earned $0.76 earnings per share. The company’s revenue was up 19.8% on a year-over-year basis. Research analysts expect that Nu Skin Enterprises will post 3.59 earnings per share for the current fiscal year.

NUS has been the topic of a number of research analyst reports. Jefferies Financial Group restated a buy rating and set a $98.00 price objective on shares of Nu Skin Enterprises in a report on Tuesday, September 4th. Zacks Investment Research upgraded shares of Nu Skin Enterprises from a sell rating to a hold rating in a report on Monday, October 15th. DA Davidson initiated coverage on shares of Nu Skin Enterprises in a report on Tuesday, October 9th. They set a buy rating and a $92.00 price objective on the stock. Stifel Nicolaus upgraded shares of Nu Skin Enterprises from a sell rating to a hold rating and raised their price objective for the stock from $57.00 to $70.00 in a report on Thursday, August 2nd. They noted that the move was a valuation call. Finally, Citigroup set a $88.00 price objective on shares of Nu Skin Enterprises and gave the stock a buy rating in a report on Thursday. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company’s stock. Nu Skin Enterprises presently has a consensus rating of Buy and an average price target of $86.29.

In other Nu Skin Enterprises news, General Counsel D Matthew Dorny sold 2,500 shares of Nu Skin Enterprises stock in a transaction on Tuesday, September 4th. The shares were sold at an average price of $79.90, for a total value of $199,750.00. Following the sale, the general counsel now directly owns 33,871 shares in the company, valued at approximately $2,706,292.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold a total of 8,750 shares of company stock worth $712,100 over the last quarter. Company insiders own 5.20% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Nu Skin Enterprises (NUS) Releases Q4 Earnings Guidance” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The legal version of this story can be accessed at https://www.thecerbatgem.com/2018/11/08/nu-skin-enterprises-nus-releases-q4-earnings-guidance.html.

Nu Skin Enterprises Company Profile

Nu Skin Enterprises, Inc develops and distributes anti-aging personal care products and nutritional supplements under the Nu Skin and Pharmanex category brands worldwide. It provides skin care systems and targeted treatment products, including ageLOC Me customized skin care systems, ageLOC Spa systems, and ageLOC LumiSpa skin treatment and cleansing devices; and Epoch products, as well as a range of other cosmetic, personal care, and hair care products.

Read More: Closed-End Mutual Funds (CEFs)

Earnings History and Estimates for Nu Skin Enterprises (NYSE:NUS)

Receive News & Ratings for Nu Skin Enterprises Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nu Skin Enterprises and related companies with MarketBeat.com's FREE daily email newsletter.